Business
OTC Markets Hosts Virtual Investor Presentation with Jim Frakes, CEO and CFO of Aethlon Medical, and M. Marin, Senior Analyst at Zacks SCR
NASDAQ: AEMD Lili Elston: Hello, and welcome to the Life Sciences Investor Forum . On behalf of OTC Markets and our co-host, Zacks Small Cap Research, we are very pleased you've joined us. The next presentation of the day is from Aethlon Medical . Their session will be moderated by M. Marin, Senior Analyst with Zacks Small Cap Research . Please note, you may submit questions for the presenter.
About this update from Aethlon Medical, Inc.
[{"type":"text","content":"NASDAQ: AEMD","length":12,"tagName":"p"},{"type":"text","content":"Lili Elston: Hello, and welcome to the Life Sciences Investor Forum. On behalf of OTC Markets and our co-host, Zacks Small Cap Research, we are very pleased you've joined us. The next presentation of the day is from Aethlon Medical. Their session will be moderated by M. Marin, Senior Analyst with Zacks Small Cap Research. Please note, you may submit questions for the presenter. You can also view a company's availability for one-on-one meetings by clicking Book a Meeting. At this point, I am very pleased to welcome Jim Frakes, Chief Executive Officer and Chief Financial Officer of Aethlon Medical (NASDAQ: AEMD). Welcome, Jim and M. Marin.","length":653,"tagName":"p"},{"type":"text","content":"Jim Frakes: Thank you, Lily.","length":28,"tagName":"p"},{"type":"text","content":"M. Marin: Thank you. Jim, we're talking about Aethlon Medical at a very exciting point in the company's development. Can you talk to us a little bit about your lead asset, about the Hemopurifier, and what makes it unique?","length":234,"tagName":"p"},{"type":"text","content":"JF: I'm happy to. And thanks, everybody, for taking time out of your day to learn more about Aethlon Medical. If you can see on the camera, I'm holding one of our products. We make a medical device called a Hemopurifier. It's designed to remove harmful viruses and cancerous particles called exosomes or extracellular vesicles from the bloodstream. This device is hooked to a blood-pumping mechanism, usually a dialysis machine or a CRRT machine. There are a number of blood-pumping devices in hospitals and clinics worldwide, and it plugs in. We only need the blood pump aspect of those machines. We don't need the other pumping issues that a dialysis machine would have. And we have breakthrough device designations from the FDA for life-threatening viruses with no prescribed therapy or life-threatening oncologic situations. The origin of the device was in virology. We did a lot of work in hepatitis C to prove the concept and help some patients. However, I focused the company on oncology, on cancer, and we're doing a clinical trial, a safety trial, in Australia at the moment. We're about two-thirds of the way through. It's going well.","length":1172,"tagName":"p"},{"type":"text","co...